Clinical Trial Update: A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for MG4101, an allogeneic natural killer cell therapy, in intermediate-stage hepatocellular carcinoma (HCC) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MG4101 (ex vivo expanded allogeneic NK cell therapy)

Snippet

Sponsor: GC Cell Corporation | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED